Red and white meat have equally harmful effects on blood cholesterol levels, according to research published in the American Journal of Clinical Nutrition, contradicting the popular idea that lighter proteins like chicken are more heart-healthy than their counterparts like beef and lamb.
An updated cost-effectiveness analysis of evolocumab suggests that while treatment with the PCSK9 inhibitor may always be somewhat costly, it remains effective in hard-to-treat patients and its reduced list price meets cost-effectiveness thresholds across a range of CV events in patients with very-high-risk atherosclerotic CVD.
The U.S. FDA on May 29 granted Amarin’s Vascepa (icosapent ethyl) priority review for a supplemental indication that would state the medication reduces cardiovascular risk in addition to helping patients manage elevated triglyceride levels.
A population-based cohort study out of France has identified a link between the consumption of ultra-processed foods and CVD, with a higher intake of sweet and starchy snacks translating to increased risks for cardiovascular, coronary heart and cerebrovascular diseases.
Millennials in their mid-thirties are less healthy than Generation Xers were at the same age, a recent analysis by Blue Cross Blue Shield found—a gap driven largely by poorer mental, cardiovascular and endocrine health outcomes in the younger generation.
Research backed by Brazil’s Sao Paulo Research Foundation found overweight teenagers face the same increased risk of developing heart disorders as their obese counterparts—a conclusion that contradicts the popular idea that the heavier a person is, the higher their CV risk.
Type 2 diabetes patients who undergo gastric bypass surgery as teenagers are more likely to achieve remission of their diabetes and hypertension in adulthood than adults who attempt the same procedure years later, according to a study funded by the National Institutes of Health.
More than one-third of statin patients still fail to reach healthy LDL-cholesterol levels a year and a half after initiating treatment, leaving them vulnerable to adverse CV events and thousands of dollars in medical bills, according to a report in the Journal of Managed Care & Specialty Pharmacy.
Diabetic ketoacidosis is more prevalent in the U.S. than it is in Canada, according to a joint analysis from Harvard Medical School, the Cambridge Health Alliance, City University of New York and the University of Manitoba.